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treatment. Image matching was performed initially using the 
auto match feature on the TomoTherapy platform and 
positioning was then refined by the treating radiographers. In 
addition to the initial radiographer who performed matching 
at time of treatment, a further two radiographers repeated 
the image matching process in order to provide information 
about inter-observer variability. 
Results: The results of intra-fraction motion include 
components both of positional change and also residual error 
in inter-observer image matching. The inter-observer 
variation had a standard deviation of 0.6mm left-right (LR), 
0.3mm anterior-posterior (AP) and 0.9mm cranio-caudal (CC). 
Intra-fraction motion had a mean positional change 
approximately 0 in LR and AP and 0.6mm CC. The standard 
deviations were 0.7, 0.6 and 1.0mm in LR, AP and CC 
directions. Using the standard van Herk PTV margin recipe1, 
the margin required to allow for these two components of 
uncertainty is 2.3mm LR, 1.7mm AP and 3.4 mm CC. 
Conclusions: The PTV margin component attributable to 
intra-fraction motion and inter-observer matching is bigger 
than expected, and bigger than used. When using high dose 
single fraction radiosurgery, the standard PTV margin recipe 
may be unnecessarily generous. Work is on-going to resolve 
the difference between the ‘ideal’ PTV margin and the 
‘clinically practical’ margin currently in use. 
References: 
1. Van Herk et al. The probability of correct target dosage: 
dose-population histograms for deriving treatment margins in 
radiotherapy IJROBP 47: 1121-1135, 2000. 
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Purpose/Objective: To evaluate the safety of Stereotactic 
Body Radiotherapy (SBRT) of bone metastases in 
oligometastatic disease and to investigate possible predictive 
factors of local control (LC), progression disease free survival 
(PDFS) and overall survival (OS).  
Materials and Methods: Main eligibility criteria were number 
of metastatic sites ≤5, controlled primary tumor with no 
evidence of progression under systemic therapies, exclusion 
of surgery and no previous radiotherapy of the lesion of 
interest. Patients were classified into two categories: only 
bone (BOD) and outside bone oligometastatic disease (OBOD). 
SBRT was delivered only to bone lesions using two different 
schedules: 24Gy/1fraction or 27Gy/3 fractions. 
Results: Between January 2010 and December 2013, 40 
patients were enrolled in our study. The most frequent 
primary tumors were prostate (40%), breast (17,5%) and lung 
cancer (15%). Two patients experienced severe late toxicity 
(fracture of the treated site). LC was longer among 
'Responders' than 'Not responders' lesions (94,2% and 91,2% 
versus 50% and 16,6% at 1 and 2 years, respectively) 
(p=0,004). The multivariate analysis of PDFS showed a 
significant correlation with PTV volume (p=0,003) and 
Oligometastatic Status (p=0,002). The multivariate analysis of 
OS, confirmed a statistical significant value of the 
Oligometastatic Status (p=0,002) whereas no correlation was 
proved for PTV volume (p=0,065).  
Conclusions: SBRT of bone metastases is safe with a low 
incidence of severe toxicity. PET response has proven to be a 
strong predictive factor of LC whereas the BOD status and the 
small size of bone metastases might identify a subset of 
oligometastatic patients at better prognosis. 
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Purpose/Objective: The aim of this study is to present an 
innovative QA methodology for patient-specific plan 
verification through true measurements of DVHs and 
comparisons with the corresponding TPS-calculated DVHs. 
Materials and Methods: 3D-printing technology and polymer 
gel dosimetry were combined in a unique way in order to 
construct a patient-specific QA phantom (patient-specific 
dosimetry phantom - PSDP). The selected patient planning-CT 
scans were used for the construction of a patient-specific 3D-
printed model (external surface and bone structures). The 
3D-printed model was subsequently filled with Vinyl-
Pyrrolidone (VIPAR) polymer gel. The constructed PSDP was 
then treated as if it the real patient, i.e. 'immobilization', 
set-up, image guidance (e.g. CBCT) and irradiation were 
implemented on the phantom. The irradiated PSDP was then 
MRI-scanned (derivation of T2-maps). The T2-maps of the 
PSDP contain dosimetric information that was extracted by 
analyzing the polymer gel dosimetry data. These PSDP T2-
maps that contain dosimetric information, were subsequently 
imported to the TPS and were registered/fused to the real 
patient planning-CT scans and RStructure dicom-RT data. This 
way, the PSDP measured dose pattern was spatially 
correlated with the real patient RStructure information, 
allowing the measurements of DVHs.  
Results: True patient-specific DVHs measurements were 
implemented following the proposed methodology. DVHs 
measurements were directly compared with the 
corresponding TPS-calculated DVHs. The QA and evaluation of 
the validity of overall treatment chain, of the treatment 
outcome and patient safety was feasible. 
Conclusions: True patient-specific DVHs can be measured for 
the first time and compared against the TPS-calculated 
corresponding DVHs, following the proposed methodology. 
Patient-specific treatment outcome and patient safety could 
